Browsing Tag
GPR119 agonist
1 post
MetaVia unveils breakthrough Phase 2a data showing vanoglipel improves liver markers and glucose control in MASH patients
Find out how MetaVia’s vanoglipel improved liver enzymes and glucose control in its Phase 2a MASH trial — see why investors are taking notice today.